References: 

• 1. Alzheimer A, Stelzmann RA, Schnitzlein HN, et al. (1995) An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 8: 429-431.    
• 2. (2013) 2013 Alzheimer's disease facts and figures. Alzheimers Dement 9: 208-245.    
• 3. Brookmeyer R, Johnson E, Ziegler-Graham K, et al. (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3: 186-191.    
• 4. Martins RN, Robinson PJ, Chleboun JO, et al. (1991) The molecular pathology of amyloid deposition in Alzheimer's disease. Mol Neurobiol 5: 389-398.    
• 5. Masters CL, Multhaup G, Simms G, et al. (1985) Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. Embo J 4: 2757-2763.
• 6. Schweers O, Mandelkow EM, Biernat J, et al. (1995) Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc Natl Acad Sci U S A 92: 8463-8467.    
• 7. Goedert M, Jakes R, Spillantini MG, et al. (1996) Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383: 550-553.    
• 8. Villemagne VL, Pike KE, Darby D, et al. (2008) Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46: 1688-1697.    
• 9. Chien DT, Bahri S, Szardenings AK, et al. (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34: 457-468.
• 10. Maruyama M, Shimada H, Suhara T, et al. (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79: 1094-1108.    
• 11. Rentz DM, Parra Rodriguez MA, Amariglio R, et al. (2013) Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review. Alzheimers Res Ther 5: 58.    
• 12. Baumgart M, Snyder HM, Carrillo MC, et al. (2015) Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement.
• 13. Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10: 819-828.    
• 14. Selkoe DJ (1996) Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 271: 18295-18298.    
• 15. Glenner GG, Wong CW (1984) Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122: 1131-1135.    
• 16. Mann DM, Esiri MM (1989) The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 89: 169-179.    
• 17. Jorm AF, Korten AE, Henderson AS (1987) The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 76: 465-479.    
• 18. Hebert LE, Weuve J, Scherr PA, et al. (2013) Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 80: 1778-1783.    
• 19. (2015) 2015 Alzheimer's disease facts and figures. Alzheimers Dement 11: 332-384.    
• 20. Lukiw WJ (2004) Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling. Neurochem Res 29: 1287-1297.    
• 21. Smith MA, Nunomura A, Lee HG, et al. (2005) Chronological primacy of oxidative stress in Alzheimer disease. Neurobiol Aging 26: 579-580; discussion 587-595.    
• 22. Overmyer M, Helisalmi S, Soininen H, et al. (1999) Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue. Acta Neuropathol (Berl) 97: 383-392.    
• 23. Currais A (2015) Ageing and inflammation - A central role for mitochondria in brain health and disease. Ageing Res Rev 21: 30-42.    
• 24. Mielke MM, Vemuri P, Rocca WA (2014) Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol 6: 37-48.
• 25. Chapman RM, Mapstone M, Gardner MN, et al. (2011) Women have farther to fall: gender differences between normal elderly and Alzheimer's disease in verbal memory engender better detection of Alzheimer's disease in women. J Int Neuropsychol Soc 17: 654-662.    
• 26. Green PS, Simpkins JW (2000) Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 18: 347-358.    
• 27. Jones KJ, Brown TJ, Damaser M (2001) Neuroprotective effects of gonadal steroids on regenerating peripheral motoneurons. Brain Res Brain Res Rev 37: 372-382.    
• 28. Wise PM, Dubal DB, Wilson ME, et al. (2001) Minireview: neuroprotective effects of estrogen-new insights into mechanisms of action. Endocrinology 142: 969-973.
• 29. Strittmatter WJ, Saunders AM, Schmechel D, et al. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90: 1977-1981.    
• 30. Saunders AM, Strittmatter WJ, Schmechel D, et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43: 1467-1472.    
• 31. Corder EH, Saunders AM, Strittmatter WJ, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.    
• 32. McGeer PL, Walker DG, Pitas RE, et al. (1997) Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates beta- amyloid protein activation of complement in vitro. Brain Res 749: 135-138.    
• 33. Prince JA, Zetterberg H, Andreasen N, et al. (2004) APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 62: 2116-2118.    
• 34. Tiraboschi P, Hansen LA, Masliah E, et al. (2004) Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 62: 1977-1983.    
• 35. Lovestone S, Anderton BH, Hartley C, et al. (1996) The intracellular fate of apolipoprotein E is tau dependent and apoe allele-specific. Neuroreport 7: 1005-1008.    
• 36. Tesseur I, Van Dorpe J, Spittaels K, et al. (2000) Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol 156: 951-964.    
• 37. Arendt T, Schindler C, Bruckner MK, et al. (1997) Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J Neurosci 17: 516-529.
• 38. Burkhardt MS, Foster JK, Laws SM, et al. (2004) Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4. J Alzheimers Dis 6: 221-228.
• 39. Patterson CE, Todd SA, Passmore AP (2011) Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. Pharmacogenomics J 11: 444-450.    
• 40. Petersen RC, Thomas RG, Grundman M, et al. (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379-2388.    
• 41. Bettens K, Sleegers K, Van Broeckhoven C (2013) Genetic insights in Alzheimer's disease. Lancet Neurol 12: 92-104.    
• 42. Norton S, Matthews FE, Barnes DE, et al. (2014) Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol 13: 788-794.    
• 43. Van Den Heuvel C, Thornton E, Vink R (2007) Traumatic brain injury and Alzheimer's disease: a review. Prog Brain Res 161: 303-316.    
• 44. Solomon A, Kareholt I, Ngandu T, et al. (2007) Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 68: 751-756.    
• 45. Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B (2015) Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci 9: 124.
• 46. Organization WH (2015) Global Strategy on Diet, Physical Activity and Health.
• 47. Warburton DE, Nicol CW, Bredin SS (2006) Health benefits of physical activity: the evidence. CMAJ 174: 801-809.    
• 48. Beckett MW, Ardern CI, Rotondi MA (2015) A meta-analysis of prospective studies on the role of physical activity and the prevention of Alzheimer's disease in older adults. BMC Geriatr 15: 9.    
• 49. Reiner M, Niermann C, Jekauc D, et al. (2013) Long-term health benefits of physical activity--a systematic review of longitudinal studies. BMC Public Health 13: 813.    
• 50. Angevaren M, Aufdemkampe G, Verhaar HJ, et al. (2008) Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev: CD005381.
• 51. Carter ND, Khan KM, McKay HA, et al. (2002) Community-based exercise program reduces risk factors for falls in 65- to 75-year-old women with osteoporosis: randomized controlled trial. CMAJ 167: 997-1004.
• 52. Lynch NA, Ryan AS, Evans J, et al. (2007) Older elite football players have reduced cardiac and osteoporosis risk factors. Med Sci Sports Exerc 39: 1124-1130.    
• 53. Vuori IM (2001) Dose-response of physical activity and low back pain, osteoarthritis, and osteoporosis. Med Sci Sports Exerc 33: S551-586; discussion 609-510.    
• 54. Tan ZS, Seshadri S, Beiser A, et al. (2005) Bone mineral density and the risk of Alzheimer disease. Arch Neurol 62: 107-111.    
• 55. Zhang Y, Seshadri S, Ellison RC, et al. (2001) Bone mineral density and verbal memory impairment: Third National Health and Nutrition Examination Survey. Am J Epidemiol 154: 795-802.    
• 56. Yaffe K, Browner W, Cauley J, et al. (1999) Association between bone mineral density and cognitive decline in older women. J Am Geriatr Soc 47: 1176-1182.    
• 57. Gunstad J, Paul RH, Cohen RA, et al. (2007) Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry 48: 57-61.    
• 58. Gustafson D, Lissner L, Bengtsson C, et al. (2004) A 24-year follow-up of body mass index and cerebral atrophy. Neurology 63: 1876-1881.    
• 59. Jagust W, Harvey D, Mungas D, et al. (2005) Central obesity and the aging brain. Arch Neurol 62: 1545-1548.
• 60. Kivipelto M, Ngandu T, Fratiglioni L, et al. (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62: 1556-1560.
• 61. Whitmer RA, Gunderson EP, Barrett-Connor E, et al. (2005) Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. Bmj 330: 1360.    
• 62. Sohrabi HR, Bates KA, Weinborn M, et al. (2015) Bone mineral density, adiposity, and cognitive functions. Front Aging Neurosci 7: 16.
• 63. Koudinov AR, Berezov TT, Kumar A, et al. (1998) Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin Chim Acta 270: 75-84.    
• 64. Koudinov AR, Koudinova NV, Kumar A, et al. (1996) Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: Associations with high density lipoproteins. Biochem Biophys Res Commun 223: 592-597.    
• 65. Eapen DJ, Kalra GL, Rifai L, et al. (2010) Raising HDL cholesterol in women. Int J Womens Health 1: 181-191.
• 66. Bates KA, Sohrabi HR, Rodrigues M, et al. (2009) Association of Cardiovascular Factors and Alzheimer's Disease Plasma Amyloid-beta Protein in Subjective Memory Complainers. J Alzheimers Dis 17: 305-318.
• 67. Atzmon G, Gabriely I, Greiner W, et al. (2002) Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J Gerontol A Biol Sci Med Sci 57: M712-715.    
• 68. Crichton GE, Elias MF, Davey A, et al. (2014) Higher HDL cholesterol is associated with better cognitive function: the Maine-Syracuse study. J Int Neuropsychol Soc 20: 961-970.    
• 69. Singh-Manoux A, Gimeno D, Kivimaki M, et al. (2008) Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife. The Whitehall II study. Arterioscler Thromb Vasc Biol 28: 1557-1563.
• 70. Ward MA, Bendlin BB, McLaren DG, et al. (2010) Low HDL Cholesterol is Associated with Lower Gray Matter Volume in Cognitively Healthy Adults. Front Aging Neurosci 2.
• 71. Biessels GJ, Kappelle LJ (2005) Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33: 1041-1044.
• 72. Gatto NM, Henderson VW, St John JA, et al. (2008) Metabolic syndrome and cognitive function in healthy middle-aged and older adults without diabetes. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 15: 627-641.    
• 73. Tomlinson DR, Gardiner NJ (2008) Glucose neurotoxicity. Nat Rev Neurosci 9: 36-45.    
• 74. Craft S, Asthana S, Newcomer JW, et al. (1999) Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 56: 1135-1140.    
• 75. Craft S, Newcomer J, Kanne S, et al. (1996) Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 17: 123-130.    
• 76. Kulstad JJ, Green PS, Cook DG, et al. (2006) Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology 66: 1506-1510.    
• 77. Ibanez J, Izquierdo M, Arguelles I, et al. (2005) Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care 28: 662-667.    
• 78. Knowler WC, Barrett-Connor E, Fowler SE, et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403.    
• 79. Cotman CW, Berchtold NC, Christie LA (2007) Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci 30: 464-472.    
• 80. Kuipers SD, Bramham CR (2006) Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Devel 9: 580-586.
• 81. Neeper SA, Gomez-Pinilla F, Choi J, et al. (1996) Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res 726: 49-56.    
• 82. Oliff HS, Berchtold NC, Isackson P, et al. (1998) Exercise-induced regulation of brain-derived neurotrophic factor (BDNF) transcripts in the rat hippocampus. Brain Res Mol Brain Res 61: 147-153.    
• 83. Widenfalk J, Olson L, Thoren P (1999) Deprived of habitual running, rats downregulate BDNF and TrkB messages in the brain. Neurosci Res 34: 125-132.    
• 84. Vaynman S, Ying Z, Gomez-Pinilla F (2004) Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur J Neurosci 20: 2580-2590.    
• 85. Vaynman SS, Ying Z, Yin D, et al. (2006) Exercise differentially regulates synaptic proteins associated to the function of BDNF. Brain Res 1070: 124-130.    
• 86. Kolb EM, Rezende EL, Holness L, et al. (2013) Mice selectively bred for high voluntary wheel running have larger midbrains: support for the mosaic model of brain evolution. J Exp Biol 216: 515-523.    
• 87. Carro E, Nunez A, Busiguina S, et al. (2000) Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci 20: 2926-2933.
• 88. Ding Q, Vaynman S, Akhavan M, et al. (2006) Insulin-like growth factor I interfaces with brain-derived neurotrophic factor-mediated synaptic plasticity to modulate aspects of exercise-induced cognitive function. Neuroscience 140: 823-833.    
• 89. McCusker RH, McCrea K, Zunich S, et al. (2006) Insulin-like growth factor-I enhances the biological activity of brain-derived neurotrophic factor on cerebrocortical neurons. J Neuroimmunol 179: 186-190.    
• 90. Carro E, Torres-Aleman I (2004) The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 490: 127-133.    
• 91. Erickson KI, Raji CA, Lopez OL, et al. (2010) Physical activity predicts gray matter volume in late adulthood: the Cardiovascular Health Study. Neurology 75: 1415-1422.    
• 92. Bugg JM, Head D (2011) Exercise moderates age-related atrophy of the medial temporal lobe. Neurobiol Aging 32: 506-514.    
• 93. Boyle CP, Raji CA, Erickson KI, et al. (2015) Physical activity, body mass index, and brain atrophy in Alzheimer's disease. Neurobiol Aging 36 Suppl 1: S194-202.
• 94. Rovio S, Spulber G, Nieminen LJ, et al. (2010) The effect of midlife physical activity on structural brain changes in the elderly. Neurobiol Aging 31: 1927-1936.    
• 95. Erickson KI, Voss MW, Prakash RS, et al. (2011) Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A 108: 3017-3022.    
• 96. Burns JM, Cronk BB, Anderson HS, et al. (2008) Cardiorespiratory fitness and brain atrophy in early Alzheimer disease. Neurology 71: 210-216.    
• 97. Honea RA, Thomas GP, Harsha A, et al. (2009) Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer disease. Alzheimer Dis Assoc Disord 23: 188-197.    
• 98. van Praag H, Shubert T, Zhao C, et al. (2005) Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci 25: 8680-8685.    
• 99. Albeck DS, Sano K, Prewitt GE, et al. (2006) Mild forced treadmill exercise enhances spatial learning in the aged rat. Behav Brain Res 168: 345-348.    
• 100. Kramer AF, Erickson KI (2007) Capitalizing on cortical plasticity: influence of physical activity on cognition and brain function. Trends Cogn Sci 11: 342-348.    
• 101. Heyn P, Abreu BC, Ottenbacher KJ (2004) The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 85: 1694-1704.    
• 102. Colcombe S, Kramer AF (2003) Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychol Sci 14: 125-130.    
• 103. Stones MJ, Kozma A (1989) Age, exercise, and coding performance. Psychol Aging 4: 190-194.    
• 104. Kamijo K, Takeda Y, Hillman CH (2011) The relation of physical activity to functional connectivity between brain regions. Clin Neurophysiol 122: 81-89.    
• 105. Burdette JH, Laurienti PJ, Espeland MA, et al. (2010) Using network science to evaluate exercise-associated brain changes in older adults. Front Aging Neurosci 2: 23.
• 106. Voss MW, Prakash RS, Erickson KI, et al. (2010) Plasticity of brain networks in a randomized intervention trial of exercise training in older adults. Front Aging Neurosci 2.
• 107. Strawbridge WJ, Deleger S, Roberts RE, et al. (2002) Physical activity reduces the risk of subsequent depression for older adults. Am J Epidemiol 156: 328-334.    
• 108. Lampinen P, Heikkinen E (2003) Reduced mobility and physical activity as predictors of depressive symptoms among community-dwelling older adults: an eight-year follow-up study. Aging Clin Exp Res 15: 205-211.    
• 109. Lee Y, Park K (2008) Does physical activity moderate the association between depressive symptoms and disability in older adults? Int J Geriatr Psychiatry 23: 249-256.    
• 110. Yoshiuchi K, Nakahara R, Kumano H, et al. (2006) Yearlong physical activity and depressive symptoms in older Japanese adults: cross-sectional data from the Nakanojo study. Am J Geriatr Psychiatry 14: 621-624.    
• 111. Salguero A, Martinez-Garcia R, Molinero O, et al. (2011) Physical activity, quality of life and symptoms of depression in community-dwelling and institutionalized older adults. Arch Gerontol Geriatr 53: 152-157.    
• 112. Lee H, Lee JA, Brar JS, et al. (2014) Physical activity and depressive symptoms in older adults. Geriatr Nurs 35: 37-41.    
• 113. Maki Y, Ura C, Yamaguchi T, et al. (2012) Effects of intervention using a community-based walking program for prevention of mental decline: a randomized controlled trial. J Am Geriatr Soc 60: 505-510.    
• 114. Penninx BW, Rejeski WJ, Pandya J, et al. (2002) Exercise and depressive symptoms: a comparison of aerobic and resistance exercise effects on emotional and physical function in older persons with high and low depressive symptomatology. J Gerontol B Psychol Sci Soc Sci 57: P124-132.    
• 115. Teixeira CM, Vasconcelos-Raposo J, Fernandes HM, et al. (2013) Physical Activity, Depression and Anxiety Among the Elderly. Social Indicators Research 113: 307-318.    
• 116. Lazarov O, Robinson J, Tang YP, et al. (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120: 701-713.    
• 117. Adlard PA, Perreau VM, Pop V, et al. (2005) Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci 25: 4217-4221.    
• 118. Kemppainen NM, Aalto S, Wilson IA, et al. (2006) Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 67: 1575-1580.    
• 119. Klunk WE, Engler H, Nordberg A, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319.    
• 120. Klunk WE, Lopresti BJ, Ikonomovic MD, et al. (2005) Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25: 10598-10606.    
• 121. Liang KY, Mintun MA, Fagan AM, et al. (2010) Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol 68: 311-318.    
• 122. Vemuri P, Lesnick TG, Przybelski SA, et al. (2012) Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann Neurol 72: 730-738.    
• 123. Brown BM, Peiffer JJ, Taddei K, et al. (2013) Physical activity and amyloid-beta plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Mol Psychiatry 18: 875-881.    
• 124. Okonkwo OC, Schultz SA, Oh JM, et al. (2014) Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology 83: 1753-1760.    
• 125. Bennet AM, Di Angelantonio E, Ye Z, et al. (2007) Association of apolipoprotein E genotypes with lipid levels and coronary risk. Jama 298: 1300-1311.    
• 126. Mahley RW, Nathan BP, Pitas RE (1996) Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease. Ann N Y Acad Sci 777: 139-145.
• 127. Weisgraber KH (1994) Apolipoprotein E: structure-function relationships. Adv Protein Chem 45: 249-302.    
• 128. Weisgraber KH, Mahley RW (1996) Human apolipoprotein E: the Alzheimer's disease connection. Faseb J 10: 1485-1494.
• 129. Yaffe K, Haan M, Byers A, et al. (2000) Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 54: 1949-1954.    
• 130. Szekely CA, Breitner JC, Fitzpatrick AL, et al. (2008) NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 70: 17-24.    
• 131. Qiu C, Winblad B, Fastbom J, et al. (2003) Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. Neurology 61: 655-660.    
• 132. Rovio S, Kareholt I, Helkala EL, et al. (2005) Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 4: 705-711.    
• 133. Deeny SP, Poeppel D, Zimmerman JB, et al. (2008) Exercise, APOE, and working memory: MEG and behavioral evidence for benefit of exercise in epsilon4 carriers. Biol Psychol 78: 179-187.    
• 134. Etnier JL, Caselli RJ, Reiman EM, et al. (2007) Cognitive performance in older women relative to ApoE-epsilon4 genotype and aerobic fitness. Med Sci Sports Exerc 39: 199-207.    
• 135. Kivipelto M, Rovio S, Ngandu T, et al. (2008) Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med 12: 2762-2771.    
• 136. Niti M, Yap KB, Kua EH, et al. (2008) Physical, social and productive leisure activities, cognitive decline and interaction with APOE-epsilon 4 genotype in Chinese older adults. Int Psychogeriatr 20: 237-251.
• 137. Schuit AJ, Feskens EJ, Launer LJ, et al. (2001) Physical activity and cognitive decline, the role of the apolipoprotein e4 allele. Med Sci Sports Exerc 33: 772-777.
• 138. Yang SY, Weng PH, Chen JH, et al. (2014) Leisure activities, apolipoprotein E e4 status, and the risk of dementia. J Formos Med Assoc.
• 139. Luck T, Riedel-Heller SG, Luppa M, et al. (2014) Apolipoprotein E epsilon 4 genotype and a physically active lifestyle in late life: analysis of gene-environment interaction for the risk of dementia and Alzheimer's disease dementia. Psychol Med 44: 1319-1329.    
• 140. Podewils LJ, Guallar E, Kuller LH, et al. (2005) Physical Activity, APOE Genotype, and Dementia Risk: Findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 161: 639-651.    
• 141. Lindsay J, Laurin D, Verreault R, et al. (2002) Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156: 445-453.    
• 142. Sabia S, Kivimaki M, Kumari M, et al. (2010) Effect of Apolipoprotein E epsilon4 on the association between health behaviors and cognitive function in late midlife. Mol Neurodegener 5: 23.    
• 143. Taaffe DR, Irie F, Masaki KH, et al. (2008) Physical activity, physical function, and incident dementia in elderly men: the Honolulu-Asia Aging Study. J Gerontol A Biol Sci Med Sci 63: 529-535.    
• 144. Smith JC, Nielson KA, Woodard JL, et al. (2014) Physical activity reduces hippocampal atrophy in elders at genetic risk for Alzheimer's disease. Front Aging Neurosci 6: 61.
• 145. Head D, Bugg JM, Goate AM, et al. (2012) Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. Arch Neurol 69: 636-643.    
• 146. Nichol K, Deeny SP, Seif J, et al. (2009) Exercise improves cognition and hippocampal plasticity in APOE epsilon4 mice. Alzheimers Dement 5: 287-294.    
• 147. Buttini M, Yu GQ, Shockley K, et al. (2002) Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J Neurosci 22: 10539-10548.
• 148. Allen SJ, MacGowan SH, Tyler S, et al. (1997) Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neurosci Lett 239: 33-36.    
• 149. Scarmeas N, Habeck C, Anderson KE, et al. (2004) Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon4 allele). Am J Geriatr Psychiatry 12: 596-605.
• 150. Rimajova M, Lenzo NP, Wu J-S, et al. (2007) Fluoro-2-deoxy-D-glucose (FDG)-PET in APOEε4 carriers in the Australian population. Journal of Alzheimer's disease 13: 137-146.
• 151. Mosconi L, De Santi S, Brys M, et al. (2008) Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 63: 609-618.    
• 152. Hone E, Martins IJ, Fonte J, et al. (2003) Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimers Dis 5: 1-8.
• 153. Hone E, Martins IJ, Jeoung M, et al. (2005) Alzheimer's disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding. J Alzheimers Dis 7: 303-314.
• 154. Mazur-Kolecka B, Frackowiak J, Kowal D, et al. (2002) Oxidative protein damage in cells engaged in beta-amyloidosis is related to apoE genotype. Neuroreport 13: 465-468.    
• 155. Overmyer M, Helisalmi S, Soininen H, et al. (1999) Astrogliosis and the ApoE genotype. an immunohistochemical study of postmortem human brain tissue. Dement Geriatr Cogn Disord 10: 252-257.    
• 156. Taddei K, Clarnette R, Gandy SE, et al. (1997) Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci Lett 223: 29-32.    
• 157. Laws SM, Hone E, Gandy S, et al. (2003) Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 84: 1215-1236.    
• 158. Laws SM, Hone E, Taddei K, et al. (2002) Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol Psychiatry 7: 886-890.    
• 159. Casadei VM, Ferri C, Veglia F, et al. (1999) APOE-491 promoter polymorphism is a risk factor for late-onset Alzheimer's disease. Neurology 53: 1888-1889.
• 160. Bueller JA, Aftab M, Sen S, et al. (2006) BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry 59: 812-815.    
• 161. Lim YY, Villemagne VL, Laws SM, et al. (2014) Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study. PLoS One 9: e86498.    
• 162. Feher A, Juhasz A, Rimanoczy A, et al. (2009) Association between BDNF Val66Met polymorphism and Alzheimer disease, dementia with Lewy bodies, and Pick disease. Alzheimer Dis Assoc Disord 23: 224-228.    
• 163. Brown BM, Bourgeat P, Peiffer JJ, et al. (2014) Influence of BDNF Val66Met on the relationship between physical activity and brain volume. Neurology 83: 1345-1352.    
• 164. Teng HK, Teng KK, Lee R, et al. (2005) ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci 25: 5455-5463.    
• 165. Zhang Y, Wang B, Wan H, et al. (2013) Meta-analysis of the insulin degrading enzyme polymorphisms and susceptibility to Alzheimer's disease. Neurosci Lett 541: 132-137.    
• 166. Vargas T, Martinez-Garcia A, Antequera D, et al. (2011) IGF-I gene variability is associated with an increased risk for AD. Neurobiol Aging 32: 556 e553-511.
• 167. Braskie MN, Boyle CP, Rajagopalan P, et al. (2014) Physical activity, inflammation, and volume of the aging brain. Neuroscience 273: 199-209.    
• 168. Licastro F, Porcellini E, Caruso C, et al. (2006) Genetic risk profiles for Alzheimer's disease: Integration of APOE genotype and variants that up-regulate inflammation. Neurobiol Aging.
• 169. Culpan D, MacGowan SH, Ford JM, et al. (2003) Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease. Neurosci Lett 350: 61-65.    
• 170. Du Y, Dodel RC, Eastwood BJ, et al. (2000) Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology 55: 480-483.    
• 171. Grimaldi LM, Casadei VM, Ferri C, et al. (2000) Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol 47: 361-365.    
• 172. Hedley R, Hallmayer J, Groth DM, et al. (2002) Association of interleukin-1 polymorphisms with Alzheimer's disease in Australia. Ann Neurol 51: 795-797.    
• 173. Koivisto AM, Helisalmi S, Pihlajamaki J, et al. (2005) Interleukin-6 promoter polymorphism and late-onset Alzheimer's disease in the Finnish population. J Neurogenet 19: 155-161.    
• 174. Laws SM, Perneczky R, Wagenpfeil S, et al. (2005) TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum Mutat 26: 29-35.    
• 175. Lio D, Annoni G, Licastro F, et al. (2006) Tumor necrosis factor-alpha -308A/G polymorphism is associated with age at onset of Alzheimer's disease. Mech Ageing Dev 127: 567-571.    
• 176. Nicoll JA, Mrak RE, Graham DI, et al. (2000) Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 47: 365-368.    
• 177. Sciacca FL, Ferri C, Licastro F, et al. (2003) Interleukin-1B polymorphism is associated with age at onset of Alzheimer's disease. Neurobiol Aging 24: 927-931.    
• 178. Shibata N, Ohnuma T, Takahashi T, et al. (2002) Effect of IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype association study in Japanese cases. Am J Med Genet 114: 436-439.    
• 179. Ferencz B, Laukka EJ, Welmer AK, et al. (2014) The benefits of staying active in old age: physical activity counteracts the negative influence of PICALM, BIN1, and CLU risk alleles on episodic memory functioning. Psychol Aging 29: 440-449.    
• 180. Holler CJ, Davis PR, Beckett TL, et al. (2014) Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer's disease brain and correlates with neurofibrillary tangle pathology. J Alzheimers Dis 42: 1221-1227.
• 181. Xu W, Tan L, Yu JT (2014) The Role of PICALM in Alzheimer's Disease. Mol Neurobiol.
• 182. Herring A, Donath A, Yarmolenko M, et al. (2012) Exercise during pregnancy mitigates Alzheimer-like pathology in mouse offspring. Faseb J 26: 117-128.    
• 183. Parnpiansil P, Jutapakdeegul N, Chentanez T, et al. (2003) Exercise during pregnancy increases hippocampal brain-derived neurotrophic factor mRNA expression and spatial learning in neonatal rat pup. Neurosci Lett 352: 45-48.    
• 184. Horsburgh S, Robson-Ansley P, Adams R, et al. (2015) Exercise and inflammation-related epigenetic modifications: focus on DNA methylation. Exerc Immunol Rev 21: 26-41.
• 185. Kaliman P, Parrizas M, Lalanza JF, et al. (2011) Neurophysiological and epigenetic effects of physical exercise on the aging process. Ageing Res Rev 10: 475-486.    
• 186. Ntanasis-Stathopoulos J, Tzanninis JG, Philippou A, et al. (2013) Epigenetic regulation on gene expression induced by physical exercise. J Musculoskelet Neuronal Interact 13: 133-146.
• 187. Hess NCL, Dieberg G, McFarlane JR, et al. (2014) The effect of exercise intervention on cognitive performance in persons at risk of, or with, dementia: A systematic review and meta-analysis. Healthy Aging Research 3: 1-10.
• 188. Holthoff VA, Marschner K, Scharf M, et al. (2015) Effects of physical activity training in patients with Alzheimer's dementia: results of a pilot RCT study. PLoS One 10: e0121478.    
• 189. Etnier JL, Labban JD, Karper WB, et al. (2015) Innovative Research Design Exploring the Effects of Physical Activity and Genetics on Cognitive Performance in Community-Based Older Adults. J Aging Phys Act.
• 190. Lautenschlager NT, Cox KL, Flicker L, et al. (2008) Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 300: 1027-1037.    
• 191. Buchman AS, Boyle PA, Yu L, et al. (2012) Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology 78: 1323-1329.    
• 192. Zlatar ZZ, McGregor KM, Towler S, et al. (2015) Self-reported physical activity and objective aerobic fitness: differential associations with gray matter density in healthy aging. Front Aging Neurosci 7: 5.
• 193. Akbaraly TN, Portet F, Fustinoni S, et al. (2009) Leisure activities and the risk of dementia in the elderly: results from the Three-City Study. Neurology 73: 854-861.    
• 194. Scarmeas N, Levy G, Tang MX, et al. (2001) Influence of leisure activity on the incidence of Alzheimer's disease. Neurology 57: 2236-2242.    
• 195. Schooler C, Mulatu MS (2001) The reciprocal effects of leisure time activities and intellectual functioning in older people: a longitudinal analysis. Psychol Aging 16: 466-482.    
• 196. Verghese J, Lipton RB, Katz MJ, et al. (2003) Leisure activities and the risk of dementia in the elderly. N Engl J Med 348: 2508-2516.    
• 197. Barnes LL, Mendes de Leon CF, Wilson RS, et al. (2004) Social resources and cognitive decline in a population of older African Americans and whites. Neurology 63: 2322-2326.    
• 198. Bennett DA, Schneider JA, Tang Y, et al. (2006) The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol 5: 406-412.    
• 199. Trost SG, Owen N, Bauman AE, et al. (2002) Correlates of adults' participation in physical activity: review and update. Med Sci Sports Exerc 34: 1996-2001.    
• 200. Dergance JM, Calmbach WL, Dhanda R, et al. (2003) Barriers to and benefits of leisure time physical activity in the elderly: differences across cultures. J Am Geriatr Soc 51: 863-868.    
• 201. Kempermann G, Gast D, Gage FH (2002) Neuroplasticity in old age: sustained fivefold induction of hippocampal neurogenesis by long-term environmental enrichment. Ann Neurol 52: 135-143.    
• 202. Hannan AJ (2014) Environmental enrichment and brain repair: harnessing the therapeutic effects of cognitive stimulation and physical activity to enhance experience-dependent plasticity. Neuropathol Appl Neurobiol 40: 13-25.    
• 203. Ball K, Berch DB, Helmers KF, et al. (2002) Effects of cognitive training interventions with older adults: a randomized controlled trial. Jama 288: 2271-2281.    
• 204. Calero MD, Navarro E (2007) Cognitive plasticity as a modulating variable on the effects of memory training in elderly persons. Arch Clin Neuropsychol 22: 63-72.
• 205. Engvig A, Fjell AM, Westlye LT, et al. (2010) Effects of memory training on cortical thickness in the elderly. Neuroimage 52: 1667-1676.    
• 206. Rozzini L, Costardi D, Chilovi BV, et al. (2007) Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors. Int J Geriatr Psychiatry 22: 356-360.    
• 207. Zanetti O, Binetti G, Magni E, et al. (1997) Procedural memory stimulation in Alzheimer's disease: impact of a training programme. Acta Neurol Scand 95: 152-157.    
• 208. Zanetti O, Zanieri G, Di Giovanni G, et al. (2001) Effectiveness of procedural memory stimulation in mild Alzheimer's disease patients: A controlled study. Neuropsychol Rehabil 11: 263-272.    
• 209. Wilson RS, Mendes De Leon CF, Barnes LL, et al. (2002) Participation in cognitively stimulating activities and risk of incident Alzheimer disease. Jama 287: 742-748.    
• 210. Wilson RS, Scherr PA, Schneider JA, et al. (2007) Relation of cognitive activity to risk of developing Alzheimer disease. Neurology 69: 1911-1920.    
• 211. Shah T, Verdile G, Sohrabi H, et al. (2014) A combination of physical activity and computerized brain training improves verbal memory and increases cerebral glucose metabolism in the elderly. Transl Psychiatry 4: e487.    
• 212. Gates NJ, Sachdev P (2014) Is cognitive training an effective treatment for preclinical and early Alzheimer's disease? J Alzheimers Dis 42 Suppl 4: S551-559.
• 213. Ngandu T, Lehtisalo J, Solomon A, et al. (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385: 2255-2263.    
• 214. Ellis KA, Bush AI, Darby D, et al. (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 21: 672-687.    
• 215. Mueller SG, Weiner MW, Thal LJ, et al. (2005) Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 1: 55-66.    
• 216. Bateman RJ, Xiong C, Benzinger TL, et al. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367: 795-804.    
• 217. Raber J, Wong D, Buttini M, et al. (1998) Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci U S A 95: 10914-10919.    
• 218. Ungar L, Altmann A, Greicius MD (2014) Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction. Brain Imaging Behav 8: 262-273.    

show all references